Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe’s assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup

Very excited to share our preprint led by M. Levin @skoyama.bsky.social J. Woerner & with S. Damrauer assessing genome-wide pleiotropy of >1,000 clinical traits across ~1.7M individuals with nearly 30K locus-trait associations! www.medrxiv.org/content/10.1... @medrxivpreprint.bsky.social

A high polygenic risk score (PRS) for screening prostate cancer was superior to a PSA test or MRI for detecting clinically significant disease (Gleason ≥7). A big step forward for supporting utility of PRS @nejm.org www.nejm.org/doi/full/10....

I chatted to @stuartbuck.bsky.social about scientific funding in the US and Australia, organisational incentives, institutional senescence, and the joy of seeing other researchers doing clever things with data you released: goodscience.substack.com/p/interview-...